AMLX

#1804
Amylyx Pharmaceuticals, Inc. - Common Stock
14.3 5 USD
+0.91%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
13.95
14.37
Jahresspanne
4.71
18.61
Tagesänderung
+0.91%
Monatliche Änderung
-8.19%
6 month change
-2.18%
Jahresänderung
+188.73%
Vorheriger Schlusskurs
14.2 2
Open
14.0 1
Tief
13.9 5
High
14.3 7
Volumen
666
Vollständige Grafik anzeigen Full chart

Financials

Übersicht Finanzbericht Statistik Dividenden
Vierteljährlich Jährlich
Gewinn- und Verlustrechnung Bilanz Cashflow
Wert Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26 TTM

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Nachrichten